Teal Health

Teal Health operates in the Femtech and telehealth market, addressing the one in four U.S. women who are not up-to-date with their cervical cancer screenings. The company’s business model centers on providing an integrated telehealth platform combined with an at-home screening kit. The process involves a brief virtual consultation with a Teal medical provider to get a prescription, after which the kit is mailed to the user's home. After self-collecting the sample, the user mails it to a certified lab for processing. Results are delivered through the Teal portal, with telehealth follow-up provided to discuss results and coordinate further care if necessary.

The company’s flagship product is the Teal Wand™, the first and only FDA-approved at-home self-collection device for cervical cancer screening in the United States. It is designed as an alternative to the traditional in-office Pap smear, which requires a speculum. The wand enables a user to comfortably collect a vaginal sample in a few minutes, which is then tested for high-risk human papillomavirus (HPV), the primary cause of cervical cancer, using the same FDA-approved tests as doctors' offices. Clinical trials confirmed the Teal Wand's accuracy is equivalent to clinician-collected samples, detecting cervical precancer 96% of the time, with 94% of study participants preferring it over in-clinic screenings.

Teal Health has achieved significant milestones, including receiving FDA Breakthrough Device Designation and, in May 2025, full FDA approval for the Teal Wand. The company has raised a total of $23 million in funding from investors such as Emerson Collective, Forerunner Ventures, Serena Ventures, and Labcorp, which supports product development and commercialization.